Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales

被引:643
作者
Cella, D
Eton, DT
Lai, JS
Peterman, AH
Merkel, DE
机构
[1] Evanston NW Healthcare, Evanston, IL USA
[2] Northwestern Univ, Evanston, IL USA
关键词
anemia; fatigue; quality of life; clinical significance;
D O I
10.1016/S0885-3924(02)00529-8
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Magnitude differences in scores on a measure of quality of life that correspond to differences in function or clinical course are called clinically important differences (CIDs). Anchor-based and distribution-based methods were used to provide ranges of CIDs for five targeted scale scores of the Functional Assessment of Cancer Therapy-Anemia (FACT-An) questionnaire. Three samples of cancer patients were used: Sample 1 included 50 patients participating in a validation study of the FACT-An; Sample 2 included 131 patients participating in a longitudinal study of chemotherapy-induced fatigue; sample 3 included 2,402 patients enrolled in a community-based clinical trial evaluating the effectiveness and safety of a treatment for anemia. Three clinical indicators (hemoglobin level; performance status; response to treatment) were used to determine anchor-based differences. One-half of the standard deviation and 1 standard error of measurement were used as distribution-based criteria. Analyses supported the following whole number estimates Of a minimal CID for these five targeted scores: Fatigue Scale = 3.0; FACT-G total score = 4.0; FACT-An total score = 7.0; Trial Outcome Index-Fatigue = 5.0; and Trial Outcome Index-Anemia = 6.0. These estimates provide a basis for sample size estimation when planning for a clinical trial or other longitudinal study, when the purpose is to ensure detection of meaningful change over time. They can also be used in conjunction with more traditional clinical markers to assist investigators in determining treatment efficacy. (C) U.S. Cancer Pain Relief Committee, 2002.
引用
收藏
页码:547 / 561
页数:15
相关论文
共 40 条
  • [31] Stetz K M, 1995, Oncol Nurs Forum, V22, P785
  • [32] Fatigue in patients with cancer
    Stone, P
    Richards, M
    Hardy, J
    [J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 (11) : 1670 - 1676
  • [33] Cancer-related fatigue: Inevitable, unimportant and untreatable? Results of a multi-centre patient survey
    Stone, P
    Richardson, A
    Ream, E
    Smith, AG
    Kerr, DJ
    Kearney, N
    [J]. ANNALS OF ONCOLOGY, 2000, 11 (08) : 971 - 975
  • [34] Improving quality of life in patients with non-small cell lung cancer: Research experience with gemcitabine
    Thatcher, N
    Hopwood, P
    Anderson, H
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 : S8 - S13
  • [35] Webster K, 1998, ONCOLOGY-NY, V12, P697
  • [36] World Health Organization (WHO), 1990, WHO TECHN REP SER
  • [37] Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life
    Wyrwich, KW
    Nienaber, NA
    Tierney, WM
    Wolinsky, FD
    [J]. MEDICAL CARE, 1999, 37 (05) : 469 - 478
  • [38] Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life
    Wyrwich, KW
    Tierney, WM
    Wolinsky, FD
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1999, 52 (09) : 861 - 873
  • [39] Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system
    Yellen, SB
    Cella, DF
    Webster, K
    Blendowski, C
    Kaplan, E
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1997, 13 (02) : 63 - 74
  • [40] Zubrod CG., 1960, J CHRONDIS, V11, P7, DOI DOI 10.1016/0021-9681(60)90137-5